[go: up one dir, main page]

UA92327C2 - Применение n-арилдиазаспироциклических соединений для лечения зависимостей - Google Patents

Применение n-арилдиазаспироциклических соединений для лечения зависимостей

Info

Publication number
UA92327C2
UA92327C2 UAA200702904A UAA200702904A UA92327C2 UA 92327 C2 UA92327 C2 UA 92327C2 UA A200702904 A UAA200702904 A UA A200702904A UA A200702904 A UAA200702904 A UA A200702904A UA 92327 C2 UA92327 C2 UA 92327C2
Authority
UA
Ukraine
Prior art keywords
compounds
addiction
effective
significant
effects
Prior art date
Application number
UAA200702904A
Other languages
English (en)
Ukrainian (uk)
Inventor
Балвиндер Сингх БХАТТИ
Грегори Дж. Гатто
Йозеф Клюцик
Original Assignee
Таргасепт, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Таргасепт, Инк. filed Critical Таргасепт, Инк.
Publication of UA92327C2 publication Critical patent/UA92327C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Описан способ лечения лекарственной зависимости, никотиновой зависимости и/или ожирения, который включает введение N-арилдиазаспироциклического соединения или ее фармацевтически приемлемой соли.Соединение эффективно для ингибирования продуцирования и/или секреции допамина и, следовательно, эффективно для угнетения процесса физиологической "компенсации", который связан с всасыванием никотина и/или запрещенных лекарственных средств.Соединение может вводиться в эффективных количествах для ингибирования высвобождения допамина без заметных нежелательных побочных эффектов (например, таких побочных эффектов, как значимое увеличение кровяного давления и скорость сердцебиения, значимое негативное влияние на пищеварительный тракт и значимое негативное влияние на скелетные мышцы).
UAA200702904A 2004-08-20 2005-08-18 Применение n-арилдиазаспироциклических соединений для лечения зависимостей UA92327C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60347904P 2004-08-20 2004-08-20

Publications (1)

Publication Number Publication Date
UA92327C2 true UA92327C2 (ru) 2010-10-25

Family

ID=35447974

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200702904A UA92327C2 (ru) 2004-08-20 2005-08-18 Применение n-арилдиазаспироциклических соединений для лечения зависимостей

Country Status (16)

Country Link
US (1) US20060058328A1 (ru)
EP (1) EP1784184A2 (ru)
JP (1) JP2008510711A (ru)
KR (1) KR20070043008A (ru)
CN (1) CN101022801A (ru)
AU (1) AU2005277410B2 (ru)
BR (1) BRPI0514509A (ru)
CA (1) CA2575461A1 (ru)
IL (1) IL180929A0 (ru)
MX (1) MX2007002045A (ru)
NO (1) NO20070979L (ru)
NZ (1) NZ552792A (ru)
RU (1) RU2387647C9 (ru)
UA (1) UA92327C2 (ru)
WO (1) WO2006023630A2 (ru)
ZA (1) ZA200701193B (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE521512C2 (sv) * 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
ES2708551T3 (es) * 2002-12-20 2019-04-10 Niconovum Ab Material particulado que contiene nicotina con una celulosa cristalina
EP1998748B1 (en) 2006-03-16 2015-01-14 NicoNovum AB Improved snuff composition
US20080247964A1 (en) * 2006-05-08 2008-10-09 Yuelian Xu Substituted azaspiro derivatives
WO2008096746A1 (ja) * 2007-02-06 2008-08-14 Takeda Pharmaceutical Company Limited スピロ化合物およびその用途
CN101951773A (zh) * 2008-01-15 2011-01-19 塔加西普特公司 7-(3-吡啶基)-1,7-二氮杂螺[4.4]壬烷的制备和对映体分离以及外消旋体和对映体的新的盐形式
CN102070640A (zh) * 2009-11-24 2011-05-25 上海药明康德新药开发有限公司 一种1,7-二氮杂螺[4,5]壬烷及其衍生物的合成方法
KR101856046B1 (ko) * 2010-05-27 2018-06-25 카탈리스트 바이오사이언시즈, 인코포레이티드 니코틴 수용체 비-경쟁적 길항제
CN102267995A (zh) * 2010-06-04 2011-12-07 艾琪康医药科技（上海）有限公司 一种制备二氮杂螺环化合物的方法
CN102516146B (zh) * 2011-11-24 2013-10-02 爱斯特（成都）生物制药有限公司 5位为氮的四元氮杂螺环衍生物及其制备方法和用途
GB201416351D0 (en) 2014-09-16 2014-10-29 Shire Internat Gmbh Heterocyclic derivatives
GB201416352D0 (en) 2014-09-16 2014-10-29 Shire Internat Gmbh Spirocyclic derivatives
RU2635105C1 (ru) * 2016-07-15 2017-11-09 Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный университет" Способ получения 4-арил-2,7,9-триазаспиро[4.5]декан-6,8,10-трионов
CN109937204B (zh) * 2016-08-01 2022-11-25 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
AU2021282596A1 (en) 2020-06-05 2023-01-19 Kinnate Biopharma Inc. Inhibitors of fibroblast growth factor receptor kinases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3282947A (en) * 1962-05-17 1966-11-01 Geschickter Fund Med Res Unsymmetrically substituted 3, 9-diazaspiro(5, 5)undecane compounds
US4922901A (en) * 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
CA2157117C (en) * 1993-03-04 1999-01-05 Manoj C. Desai Spirocyclic piperidine derivatives
US5597919A (en) * 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
JPH11508540A (ja) * 1995-06-29 1999-07-27 ノボ ノルディスク アクティーゼルスカブ 新規の置換アザ環式またはアザ二環式化合物
US5616716A (en) * 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
US5663356A (en) * 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
US5733912A (en) * 1997-02-19 1998-03-31 Abbott Laboratories 7A-heterocycle substituted hexahydro-1H-pyrrolizine compounds useful in controlling chemical synaptic transmission
SI0970957T1 (ru) * 1998-06-12 2001-12-31 Hoffmann La Roche
JP2003514777A (ja) * 1999-10-27 2003-04-22 シーオーアール セラピューティクス インコーポレイテッド フィブリノゲン依存性血小板凝集の阻害剤としてのピリジル含有スピロ環化合物
EP1272484B1 (en) * 2000-04-10 2005-07-20 Pfizer Products Inc. Benzoamide piperidine compounds as substance p antagonists
CA2491506C (en) * 2002-07-05 2011-04-26 Targacept, Inc. N-aryl diazaspiracyclic compounds and methods of preparation and use thereof

Also Published As

Publication number Publication date
AU2005277410B2 (en) 2010-06-24
RU2007110020A (ru) 2008-09-27
WO2006023630A2 (en) 2006-03-02
AU2005277410A1 (en) 2006-03-02
KR20070043008A (ko) 2007-04-24
US20060058328A1 (en) 2006-03-16
RU2387647C2 (ru) 2010-04-27
ZA200701193B (en) 2009-09-30
RU2387647C9 (ru) 2011-05-27
CA2575461A1 (en) 2006-03-02
WO2006023630A3 (en) 2006-05-04
CN101022801A (zh) 2007-08-22
JP2008510711A (ja) 2008-04-10
MX2007002045A (es) 2007-03-29
IL180929A0 (en) 2007-07-24
NZ552792A (en) 2009-12-24
EP1784184A2 (en) 2007-05-16
BRPI0514509A (pt) 2008-06-10
NO20070979L (no) 2007-03-19

Similar Documents

Publication Publication Date Title
NO20070979L (no) Anvendelse av N-aryldiazaspirasykliske forbindelser i behandling av avhengighet
NO20050012L (no) N-aryldiazaspiracykliske forbindelser og fremgangsmater for fremstilling og anvendelse derav
IL295536B2 (en) Specific tryptamines for use in the treatment of mood disorders
EA201000365A1 (ru) Гетероциклические амиды, пригодные для лечения злокачественного новообразования и псориаза
MX2009012558A (es) Combinaciones de farmacos para el tratamiento de distrofia muscular de duchenne.
MX2008016037A (es) Uso de 2-aminotetralinas substituidas para la fabricacion de un medicamento para la prevencion, alivio y/o tratamiento de diversos tipos de dolor.
EA201100305A1 (ru) Лечение респираторных заболеваний
JP2019515908A5 (ru)
GB2454615A (en) Antidiabetic azabicyclo (3.1.0) hexan compounds
EA200800663A1 (ru) Способ и средство профилактики и лечения нарушенного дыхания во время сна
TW200635878A (en) Hydroxybiphenylcarboxylic acids and derivatives, processes for preparing them and their use
NO20050569L (no) Fremgangsmate for behandling av alvorlig hjertesvikt og medikament for dette
MY139107A (en) Substituted n-cyclohexylimidazolinones, process for their preparation and their use as medicaments.
WO2008087461B1 (en) Use of kynurenic acid and derivatives thereof in the treatment of conditions of the gastrointestinal tract accompanied by hypermotility and inflammation or gout or multiple sclerosis
MXPA05010020A (es) Derivados de oxamida.
MY142431A (en) Oxadiazolones, processes for their preparation and their use as pharmaceuticals
MXPA06013221A (es) Formulaciones en polvo para la inhalacion, las cuales contienen beta-agonistas enantiomericamente puros.
EP4389218A3 (en) Composition for treating joint disease and kit containing same
EA201990419A1 (ru) Слаборастворимый комплекс или его сольват, фармацевтическая композиция и их применение
CA2451238A1 (en) Cyclic diamine compound with 5 membered ring groups
JP2015509105A (ja) リファキシミン誘導体及びその使用
RU2016111390A (ru) Неконкурентные антагонисты никотиновых рецепторов
SG140605A1 (en) Benzothiazole derivatives
EA201000739A1 (ru) Новое медицинское применение солей 3-(2,2,2-триметилгидразиниум)пропионата
CA2515730A1 (en) Pyrrolidinohydrochinazolines